Literature DB >> 10393393

Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients.

O P Schaefer1, J M Gore.   

Abstract

Aspirin is one of the world's most commonly used medications and its use benefits many diverse conditions. Adverse reactions, however, are relatively common as well. Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction. We report 3 cases in whom aspirin was indicated for secondary prophylaxis of myocardial infarction but in whom a remote history of an untoward reaction to it prevented its initial use. These patients all underwent further evaluation of their pulmonary and allergic history and all 3 were challenged with aspirin. Two patients were found not to be sensitive and started on aspirin, the other had a classic asthmatic reaction to the drug and was successfully desensitized to aspirin allowing for its use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393393     DOI: 10.1159/000006871

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  5 in total

Review 1.  Crossreacting drugs and chemicals.

Authors:  Katharine M Woessner
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

Review 2.  The mechanisms of aspirin-intolerant asthma and its management.

Authors:  Maureen McGeehan; Robert K Bush
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 3.  Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients.

Authors:  Phil Lambrakis; Gordon F Rushworth; Jane Adamson; Stephen J Leslie
Journal:  Ther Adv Drug Saf       Date:  2011-12

Review 4.  Drug-induced angioedema without urticaria.

Authors:  A Agostoni; M Cicardi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

Review 5.  Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity.

Authors:  James S W Kong; Suzanne S Teuber; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.